Neuroendocrine Regulation of Appetite and Body Weight

Michael Wilkinson; S. Ali Imran

doi:10.1017/9781108149938.005

Chapter 4 - Neuroendocrine Regulation of Appetite and Body Weight

Published online by Cambridge University Press: 24 December 2018

Michael Wilkinson and

S. Ali Imran

Show author details

Michael Wilkinson: Affiliation:
Dalhousie University, Nova Scotia
S. Ali Imran: Affiliation:
Dalhousie University, Nova Scotia

Book contents

Get access

Type: Chapter
Information: Clinical Neuroendocrinology
An Introduction
, pp. 53 - 74

DOI: https://doi.org/10.1017/9781108149938.005 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abel, B S, Muniyappa, R, Stratton, P, Skarulis, M C, Gorden, P & Brown, R J. (2016). Effects of recombinant human leptin (Metreleptin) on nocturnal luteinizing hormone secretion in lipodystrophy patients. Neuroendocr 103, 402–407.Google Scholar

Ak, M, Sezlev, D, Sutcigil, L, Akarsu, S, Ozgen, F & Yanik, T. (2013). The investigation of leptin and hypothalamic neuropeptides role in first attack psychotic male patients: olanzapine monotherapy. Psychoneuroendocr 38, 341–347.Google Scholar

Alsalim, W, Omar, B, Pacini, G, Bizzotto, R, Mari, A & Ahrén, B. (2015). Incretin and islet hormone responses to meals of increasing size in healthy subjects. J Clin Endocr Metab 100, 561–568.Google Scholar

Angulo, M A, Butler, M G & Cataletto, M E. (2015). Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J Endocr Invest 38, 1249–1263.Google Scholar

Arango, C, Rojas, M J, Moreno, D & Parellada, M. (2002). Sibutramine for compulsive eating in hypothalamic deficiency. J Am Acad Child Adolesc Psych 41, 1147–1148.Google Scholar

Astrup, A, Rössner, S, Van Gaal, L et al., on behalf of the NN8022-1807 Study Group. (2009). Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374, 1606–1616.Google Scholar

Bak, M J, Albrechtsen, N J W, Pedersen, J et al. (2014). Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies. Diabetes Obes Metab 16, 1155–1164.Google Scholar

Bakker, N E, Wolffenbuttel, K P, Looijenga, L H & Hokken-Koelega, A C. (2015). Testes in infants with Prader-Willi syndrome: human chorionic gonadotropin treatment, surgery and histology. J Urol 193, 291–298.Google Scholar

Bakker, N E, Lindberg, A, Heissler, J et al. (2017). Growth hormone treatment in children with Prader-Willi syndrome: three years of longitudinal data in prepubertal children and adult height data from the KIGS Database. J Clin Endocr Metab 102, 1702–1711.Google Scholar

Ballon, J S, Pajvani, U B, Mayer, L E S et al. (2018). Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo. J Psychopharmacol 32, 533–540.Google Scholar

Beall, C, Hanna, L & Ellacott, K L J. (2017). CNS targets of adipokines. Compr Physiol 7, 1359–1406.Google Scholar

Benedict, C, Axelsson, T, Söderberg, S et al. (2014). Fat mass and obesity-associated gene (FTO) is linked to higher plasma levels of the hunger hormone ghrelin and lower serum levels of the satiety hormone leptin in older adults. Diabetes 63, 3955–3959.Google Scholar

Bray, G A & Gallagher, T F Jr. (1975). Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a review of the literature. Medicine 54, 301–330.Google Scholar

Brown, R J, Araujo-Vilar, D, Cheung, P T et al. (2016). The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocr Metab 101, 4500–4511.Google Scholar

Carr, R D, Larsen, M O, Jelic, K et al. (2010). Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. J Clin Endocr Metab 95, 872–878.Google Scholar

Çetinkaya, S, Güran, T, Kurnaz, E et al. (2018). A patient with proopiomelanocortin deficiency: an increasingly important diagnosis to make. J Clin Res Ped Endocr 10, 68–73.Google Scholar

Chen, K Y, Muniyappa, R, Abel, B S et al. (2015). RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals. J Clin Endocr Metab 100, 1639–1645.Google Scholar

Chou, S C & Mantzoros, C. (2014). Role of leptin in human reproductive disorders. J Endocr 223, T49–T62.Google Scholar

Colldén, G, Tschöp, M H & Müller, T D. (2017). Therapeutic potential of targeting the ghrelin pathway. Int J Mol Sci 18, 798.Google Scholar

Collet, T-H, Dubern, B, Mokrosinski, J et al. (2017). Evaluation of a melanocortin-4 receptor (MC4 R) agonist (Setmelanotide) in MC4 R deficiency. Mol Metab 6, 1321–1329.Google Scholar

Considine, R V, Sinha, M K, Heiman, M L et al. (1996). Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New Eng J Med 334, 292–295.Google Scholar

Cummings, D E, Purnell, J Q, Frayo, R S, Schmidova, K, Wisse, B E & Weigle, D S. (2001). A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50, 1714–1719.Google Scholar

Currow, D, Temel, J S, Abernethy, A, Milanowski, J, Friend, J & Fearon, K C. (2017). ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann Oncol 28, 1949–1956.Google Scholar

Davenport, R J & Wright, S. (2014). Treating obesity: is it all in the gut? Drug Discov Today 19, 845–858.Google Scholar

Deepak, D, Furlong, N J, Wilding, J P & MacFarlane, I A. (2007). Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic–pituitary disease. Postgrad Med J 83, 277–280.Google Scholar

de Lind van Wijngaarden, R F, Otten, B J, Festen, D A et al. (2008). High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome. J Clin Endocr Metab 93, 1649–1654.Google Scholar

Dhurandhar, E J. (2016). The downfalls of BMI-focused policies. Int J Obes 40, 729–730.Google Scholar

Dietrich, M O & Horvath, T L. (2010). Neural regulation of food intake and energy balance. Nature poster: www.nature.com/nrn/posters/feeding.Google Scholar

Druce, M R, Wren, A M, Park, A J et al. (2005). Ghrelin increases food intake in obese as well as lean subjects. Int J Obes 29, 1130–1136.Google Scholar

Editorial (2017). Lancet Diabetes Endocr 5, 483.Google Scholar

Farholt, S, Sode-Carlsen, R, Christiansen, J S, Østergaard, J R & Høybye, C. (2011). Normal cortisol response to high-dose synacthen and insulin tolerance test in children and adults with Prader-Willi syndrome. J Clin Endocr Metab 96, E173–E180.Google Scholar

Farooqi, I S, Matarese, G, Lord, G M et al. (2002). Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 110, 1093–1103.Google Scholar

Farooqi, I S, Keogh, J M, Yeo, G S H, Lank, E J, Cheetham, T & O’Rahilly, S. (2003). Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. New Eng J Med 348, 1085–1095.CrossRef Google Scholar PubMed

Farooqi, I S, Wangensteen, T, Collins, S et al. (2007). Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. New Engl J Med 356, 237–247.Google Scholar

Farooqi, I S & O’Rahilly, S. (2014). Human disorders of leptin action. J Endocr 223, T63–T70.CrossRef Google Scholar PubMed

Fasshauer, M & Blüher, M. (2015). Adipokines in health and disease. Trends Pharmacol Sci 36, 461–470.Google Scholar

Finan, B, Clemmensen, C & Müller, T D. (2015). Emerging opportunities for the treatment of metabolic diseases: glucagon-like peptide-1 based multi-agonists. Mol Cell Endocr 418, 42–54.Google Scholar

Fiorenza, C G, Chou, S H & Mantzoros, C S. (2011). Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocr 7, 137–150.Google Scholar

Frayling, T M, Timpson, N J, Weedon, M N et al. (2007). A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316, 889–894.Google Scholar

Friedman, J. (2016). The long road to leptin. J Clin Invest 126, 4727–4734.Google Scholar

Garcia, J M. (2017). What is next after anamorelin? Curr Opin Support Palliat Care 11, 266–271.Google Scholar

Garcia, J M & Polvino, W J. (2007). Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist 12, 594–600.CrossRef Google Scholar PubMed

Garcia, J M, Boccia, R V, Graham, C D et al. (2015). Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol 16, 108–116.Google Scholar

Gardiner, J V, Jayasena, C N & Bloom, S R. (2008). Gut hormones: a weight off your mind. J Neuroendocr 20, 834–841.Google Scholar

Gautier, J-F, Choukem, S-P & Girard, J. (2008). Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes & Metab 34, S65–S72.CrossRef Google Scholar PubMed

Goldstone, A P, Holland, A J, Butler, J V & Whittington, J E. (2012). Appetite hormones and the transition to hyperphagia in children with Prader-Willi syndrome. Int J Obes 36, 1564–1570.Google Scholar

Goodarzi, M O. (2018). Genetics of obesity: what genetic association studies have taught us about the biology of obesity and its complications. Lancet Diabetes Endocr 6, 223–236.CrossRef Google Scholar PubMed

GOV.UK (2017). www.gov.uk/government/uploads/system/uploads/attachment_data/file/613532/obes-phys-acti-diet-eng-2017-rep.pdf Google Scholar

Guerra, B, Fuentes, T, Delgado-Guerra, S et al. (2008). Gender dimorphism in skeletal muscle leptin receptors, serum leptin and insulin sensitivity. PLoS ONE 3, e3466.CrossRef Google Scholar PubMed

Halawi, H, Khemani, D, Eckert, D et al. (2017). Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastro Hepatol 2, 890–899.Google Scholar

Harz, K J, Müller, H L, Waldeck, E, Pudel, V & Roth, C. (2003). Obesity in patients with craniopharyngioma: assessment of food intake and movement counts indicating physical activity. J Clin Endocr Metab 88, 5227–5231.Google Scholar

Haqq, A M, Farooqi, I S, O’Rahilly, S et al. (2003). Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi Syndrome. J Clin Endocr Metab 88, 174–178.Google Scholar

Hay, D L, Chen, S, Lutz, T A, Parkes, D G & Roth, J D. (2015). Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev 67, 564–600.CrossRef Google Scholar PubMed

Henderson, D C, Vincenzi, B, Andrea, N V, Ulloa, M & Copeland, P M. (2015). Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiat 2, 452–464.Google Scholar

Heymsfield, S B & Wadden, T A. (2017). Mechanisms, pathophysiology, and management of obesity. New Eng J Med 376, 254–266.Google Scholar

Heymsfield, S B, Greenburg, A S, Fujioka, K et al. (1999). Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282, 1568–1575.Google Scholar

Hosojima, H, Togo, T, Odawara, T et al. (2006). Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 20, 75–79.CrossRef Google Scholar PubMed

Hotta, M, Ohwada, R, Akamizu, T, Shibasaki, T & Kangawa, K. (2012). Therapeutic potential of ghrelin in restricting-type anorexia nervosa. Methods Enzymol 514, 381–398.Google Scholar

Igaki, N, Tanaka, M & Goto, T. (2005). Markedly improved glycemic control and enhanced insulin sensitivity in a patient with type 2 diabetes complicated by a suprasellar tumor treated with pioglitazone and metformin. Intern Med 44, 832–837.Google Scholar

Inge, T H, Pfluger, P, Zeller, M et al. (2007). Gastric bypass surgery for treatment of hypothalamic obesity after craniopharyngioma therapy. Nat Clin Pract Endocr Metab 3, 606–609.Google Scholar

Irizarry, K A, Miller, M, Freemark, M & Haqq, A M. (2016). Prader Willi syndrome: genetics, metabolomics, hormonal function, and new approaches to therapy. Adv Ped 63, 47–77.CrossRef Google Scholar PubMed

Ismail, D, O’Connell, M A & Zacharin, M R. (2006). Dexamphetamine use for management of obesity and hypersomnolence following hypothalamic injury. J Ped Endocr Metab 19, 129–134.CrossRef Google Scholar PubMed

Karra, E, O’Daly, O G, Choudhury, A I et al. (2013). A link between FTO, ghrelin, and impaired brain food-cue responsivity. J Clin Invest 123, 3539–3551.Google Scholar

Kleinert, M, Clemmensen, C, Stemmer, K, Müller, T D, DiMarchi, R D & Tschöp, M H. (2017). Emerging poly-agonists for obesity and type 2 diabetes. Obesity 25, 1647–1649.Google Scholar

Krude, H, Biebermann, H, Luck, W, Horn, R, Brabant, G & Grüters, A. (1998). Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Gen 19, 155–157.Google Scholar

Krude, H & Grüters, A. (2000). Implications of pro-opiomelanocortin (POMC) mutations in humans: the POMC deficiency syndrome. Trends Endocr Metab 11, 15–22.Google Scholar

Kühnen, P, Clément, K, Wiegand, S et al. (2016). Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. New Eng J Med 375, 240–246.CrossRef Google Scholar PubMed

Kyriakidis, M, Caetano, L, Anastasiadou, N, Karasu, T & Lashen, H. (2016). Functional hypothalamic amenorrhoea: leptin treatment, dietary intervention and counselling as alternatives to traditional practice – systematic review. Europ J Obstet Gynecol Reprod Biol 198, 131–137.CrossRef Google Scholar PubMed

Licinio, J, Caglayan, S, Ozata, M et al. (2004). Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A 101, 4531–4536.CrossRef Google Scholar PubMed

Lippl, F, Erdmann, J, Steiger, A et al. (2012). Low-dose ghrelin infusion – evidence against a hormonal role in food intake. Regul Peptides 174, 26–31.Google Scholar

Locke, A E, Kahali, B, Berndt, S et al. (2015). Genetic studies of body mass index yield new insights for obesity biology. Nature 518, 197–206.Google Scholar

Loos, R J F & Yeo, G S H. (2014). The bigger picture of FTO – the first GWAS-identified obesity gene. Nat Revs Endocr 10, 51–61.CrossRef Google Scholar PubMed

Lu, M L, Wang, T N, Lin, T Y et al. (2015). Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin. Prog Neuropsychopharmacol Biol Psychiatry 58, 47–50.Google Scholar

Maffetone, P B, Rivera-Dominguez, I & Laursen, P B. (2017). Overfat adults and children in developed countries: the public heath importance of identifying excess body fat. Front public health 5, Article # 190.Google Scholar

Mancini, M C & de Melo, M E. (2017). The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg. Diabetol Metab Syndrom 9, 44.Google Scholar

Mendiratta, M S, Yang, Y, Balazs, A E et al. (2011). Early onset obesity and adrenal insufficiency associated with a homozygous POMC mutation. Int J Ped Endocr 2011: 5.Google Scholar

Messidoro, C, Elte, J W F, Cabezas, M C, van Agteren, M, Lacroix, A & de Herder, W W. (2009). Food-dependent Cushing’s syndrome. Netherlands J Med 67, 187–190.Google Scholar

Morton, G M, Meek, T H & Schwartz, M W. (2014). Neurobiology of food intake in health and disease. Nat Revs Neurosci 15, 367–378.Google Scholar

Müller, T D, Tschöp, M H & O’Rahilly, S. (2016). Metabolic precision medicines: curing POMC deficiency. Cell Metab 24, 194–195.Google Scholar

Musso, C, Cochran, E, Javor, E, Young, J, DePaoli, A M & Gorden, P. (2005). The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients. Metab Clin Exp 54, 255–263.Google Scholar

Myers, M G, Jr., Leibel, R L, Seeley, R J & Schwartz, M W. (2010). Obesity and leptin resistance: distinguishing cause from effect. Trends Endocr Metab 21, 643–651.CrossRef Google Scholar PubMed

NCD Risk Factor Collaboration (NCD-RisC). (2017). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet 390, 2627–2642.Google Scholar

Ozsu, E, Ceylaner, S & Onay, H. (2017). Early-onset severe obesity due to complete deletion of the leptin gene in a boy. J Ped Endocr Metab 30, 1227–1230.Google Scholar

Paz-Filho, G, Mastronardi, C A & Licinio, J. (2015). Leptin treatment: facts and expectations. Metab Clin Exp 64, 146–156.Google Scholar

Pigeyre, M, Yazdi, F T, Kaur, Y & Meyre, D. (2016). Recent progress in genetics, epigenetics and metagenomics unveils the pathophysiology of human obesity. Clin Sci 130, 943–986.Google Scholar

Pi-Sunyer, X, Astrup, A, Fujioka, K et al. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New Engl J Med 373, 11–22.Google Scholar

Ravussin, E, Smith, S R, Mitchell, J A et al. (2009). Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 17, 1736–1743.CrossRef Google Scholar PubMed

Rehfeld, J F. (2017). The changing concept of gut endocrinology. Endocr Develop 32, 8–19.Google Scholar

Reitman, M L. (2016). Hormone-replacement therapy for melanocyte-stimulating hormone deficiency. New Eng J Med 375, 278–279.Google Scholar

Rhea, E M, Salameh, T S, Logsdon, A F, Hanson, A J, Erickson, M A & Banks, W A. (2017). Blood-brain barriers in obesity. AAPS 19, 921–930.Google Scholar

Roth, C L, Eslamy, H, Werny, D et al. (2015). Semiquantitative analysis of hypothalamic damage on MRI predicts risk for hypothalamic obesity. Obesity 23, 1226–1233.Google Scholar

Sahin-Efe, A, Upadhyay, J, Ko, B-J et al. (2017). Irisin and leptin concentrations in relation to obesity, and developing type 2 diabetes: a cross sectional and a prospective case-control study nested in the normative aging study. Metab 79, 24–32.Google Scholar

Schorr, M & Miller, K K. (2017). The endocrine manifestations of anorexia nervosa: mechanisms and management. Nat Revs Endocr 13, 174–186.Google Scholar

Schultes, B, Ernst, B, Schmid, F & Thurnheer, M. (2009). Distal gastric bypass surgery for the treatment of hypothalamic obesity after childhood craniopharyngioma. Eur J Endocr 161, 201–206.Google Scholar

Schwartz, M W & Morton, G J. (2002). Obesity: keeping hunger at bay. Nature 418, 595–597.CrossRef Google Scholar PubMed

Schwartz, M W, Seeley, R J, Zeltser, L M et al. (2017). Obesity pathogenesis: An endocrine society scientific statement. Endocr Revs 38, 267–296.Google Scholar

Scuteri, A, Sanna, S, Chen, W-M et al. (2007). Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet 3, e115.Google Scholar

Speakman, J R. (2015). The ‘Fat Mass and Obesity Related’ (FTO) gene: mechanisms of impact on obesity and energy balance. Curr Obes Rep 4, 73–91.Google Scholar

Spiegel, K, Tasali, E, Leproult, R, Scherberg, N & Van Cauter, E. (2011). Twenty-four-hour profiles of acylated and total ghrelin: relationship with glucose levels and impact of time of day and sleep. J Clin Endocr Metab 96, 486–493.Google Scholar

Stats Canada. (2017). www5.statcan.gc.ca/cansim/a03?lang=eng&pattern=105–0508&p2=31 Google Scholar

Steinert, R E, Feinle-Bisset, C, Asarian, L, Horowitz, M, Beglinger, C & Geary, N. (2017). Ghrelin, CCK, GLP-1, and PYY (3–36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol Rev 97, 411–463.Google Scholar

Stunkard, A J, Harris, J R, Pedersen, N L & McClearn, G E. (1990). The body mass index of twins who have been reared apart. N Engl J Med 322, 1483–1487.Google Scholar

Tam, C S, Lecoultre, V & Ravussin, E. (2011). Novel strategy for the use of leptin for obesity therapy. Expert Opin Biol Ther 11, 1677–1685.Google Scholar

Tan, T, Behary, P, Tharakan, G et al. (2017). The effect of a subcutaneous infusion of GLP-1, OXM, and PYY on energy intake and expenditure in obese volunteers. J Clin Endocr Metab 102, 2364–2372.Google Scholar

The GBD Obesity Collaborators (2017). Health effects of overweight and obesity in 195 countries over 25 years. New Eng J Med 377, 13–27.Google Scholar

Thondam, S K, Cuthbertson, D J, Aditya, B S, MacFarlane, I A, Wilding, J P & Daousi, C. (2012). A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus. Clin Endocr 77, 635–637.Google Scholar

Tomiyama, A J, Hunger, J M, Nguyen-Cuu, J & Wells, C. (2016). Misclassification of cardiometabolic health when using body mass index categories in NHANES 2005–2012. Int J Obes 40, 883–886.Google Scholar

Tschöp, M, Weyer, C, Tataranni, P A, Devanarayan, V, Ravussin, E & Heiman, M L. (2001). Circulating ghrelin levels are decreased in human obesity. Diabetes 50, 707–709.Google Scholar

Tschöp, M H, Finan, B, Clemmensen, C et al. (2016). Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab 24, 51–62.Google Scholar

Tung, Y C L, Yeo, G S H, O’Rahilly, S & Coll, A P. (2014). Obesity and FTO: changing focus at a complex locus. Cell Metab 20, 710–718.Google Scholar

Uher, R & Treasure, J. (2005). Brain lesions and eating disorders. J Neurol Neurosurg Psych 76, 852–857.Google Scholar

Valette, M, Bellisle, F, Carette, C et al. (2013). Eating behaviour in obese patients with melanocortin-4 receptor mutations: a literature review. Int J Obes 37, 1027–1035.Google Scholar

Valette, M, Poitou, C, Kesse-Guyot, E et al. (2014). Association between melanocortin-4 receptor mutations and eating behaviors in obese patients: a case–control study. Int J Obes 38, 883–885.Google Scholar

Wabitsch, M, Funcke, J-B, Lennerz, B et al. (2015). Biologically inactive leptin and early-onset extreme obesity. New Engl J Med 372, 48–54.Google Scholar

World Obesity Federation (2017). Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obesity Revs 18, 715–723.Google Scholar

Yang, Q, Xiao, T, Guo, J & Su, Z. (2017). Complex relationship between obesity and the fat mass and obesity locus. Int J Biol Sci 13, 615–629.Google Scholar

Yeo, G S H. (2017). Genetics of obesity: can an old dog teach us new tricks? Diabetologia 60, 778–783.Google Scholar

Yi, X, Yuan, D, Farr, S A, Banks, W A, Poon, C-D & Kabanov, A V. (2014). Pluronic modified leptin with increased systemic circulation, brain uptake and efficacy for treatment of obesity. J Control Release 191, 34–46.Google Scholar

Zelissen, P M J, Stenlof, K, Lean, M E J, Fogteloo, J, Keulen, E T P, Wilding, J. (2005). Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabetes Obes Metab 7, 755–761.CrossRef Google Scholar PubMed

Book contents

Chapter 4 - Neuroendocrine Regulation of Appetite and Body Weight

Access options

References

Further Reading

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive